AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Apr 2015 05:30 PM
RNS
Director/PDMR Shareholding
24 Apr 2015 05:30 PM
RNS
Result of AGM
24 Apr 2015 07:02 AM
RNS
1st Quarter Results
24 Apr 2015 07:01 AM
RNS
Collaboration with Celgene on PD-L1 in haematology
24 Apr 2015 07:00 AM
RNS
AZ and Innate to collaborate in immuno-oncology
23 Apr 2015 09:00 AM
RNS
Notice of Results
17 Apr 2015 07:00 AM
RNS
Selumetinib granted Orphan Drug Designation by FDA
15 Apr 2015 07:02 AM
RNS
Tremelimumab granted Orphan Drug Designation
15 Apr 2015 07:00 AM
RNS
FDA REVIEWS SAVOR OUTCOMES STUDY RESULTS
01 Apr 2015 11:00 AM
RNS
Total Voting Rights
30 Mar 2015 03:00 PM
RNS
Director/PDMR Shareholding
19 Mar 2015 11:00 AM
RNS
Notice of AGM
19 Mar 2015 07:00 AM
RNS
COLLABORATION WITH DAIICHI SANKYO INC
18 Mar 2015 07:04 AM
RNS
POSITIVE PHASE III RESULTS FOR PT003 IN COPD
16 Mar 2015 07:00 AM
RNS
BRILINTA PEGASUS-TIMI 54 STUDY
10 Mar 2015 06:24 PM
RNS
Filing of Form 20-F with SEC
10 Mar 2015 11:00 AM
RNS
Annual Financial Report
06 Mar 2015 07:00 AM
RNS
ASTRAZENECA REFINES ITS FINANCIAL REPORTING
04 Mar 2015 11:54 AM
RNS
AZ TO PARTICIPATE IN US FDA EMDAC
03 Mar 2015 07:05 AM
RNS
Acquisition of Rights to Actavis' Portfolio
02 Mar 2015 03:00 PM
RNS
Total Voting Rights
17 Feb 2015 07:00 AM
RNS
Directorate Change
16 Feb 2015 07:00 AM
RNS
PULMICORT RESPULES® US PATENT LITIGATION DECISION
05 Feb 2015 07:02 AM
RNS
AZ to acquire Actavis' US respiratory portfolio
05 Feb 2015 07:00 AM
RNS
Final Results
04 Feb 2015 09:00 AM
RNS
Notice of Results
02 Feb 2015 02:00 PM
RNS
Total Voting Rights
22 Jan 2015 07:00 AM
RNS
MAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA
14 Jan 2015 07:43 AM
RNS
BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT
02 Jan 2015 02:00 PM
RNS
Total Voting Rights
19 Dec 2014 05:40 PM
RNS
LYNPARZA APPROVED BY THE US FDA
18 Dec 2014 07:00 AM
RNS
LYNPARZAT APPROVED IN THE EUROPEAN UNION
09 Dec 2014 07:00 AM
RNS
MOVENTIG approved in the EU for OIC
05 Dec 2014 05:03 PM
RNS
Jury verdict favours AZ in Nexium litigation
02 Dec 2014 07:00 AM
RNS
New Drug Application for IRESSA accepted by US FDA
01 Dec 2014 02:00 PM
RNS
Total Voting Rights
01 Dec 2014 02:00 PM
RNS
Blocklisting Interim Review
26 Nov 2014 07:00 AM
RNS
POSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY
24 Nov 2014 04:00 PM
RNS
Publication of Final Terms
24 Nov 2014 07:00 AM
RNS
DUAKLIR GENUAIR APPROVED IN THE EU FOR COPD
19 Nov 2014 05:00 PM
RNS
Launch and Pricing of a ?750m Bond
18 Nov 2014 07:00 AM
RNS
AZ strategy on track to deliver growth and value
17 Nov 2014 04:00 PM
RNS
Publication of Supplementary Prospectus
12 Nov 2014 07:00 AM
RNS
AMGEN & AZ POSITIVE PHASE III BRODALUMAB RESULTS
10 Nov 2014 02:27 PM
RNS
Director/PDMR Shareholding
06 Nov 2014 07:04 AM
RNS
ASTRAZENECA TO DIVEST MYALEPT TO AEGERION
06 Nov 2014 07:00 AM
RNS
3rd Quarter Results
06 Nov 2014 07:00 AM
RNS
3rd Quarter Results
05 Nov 2014 07:00 AM
RNS
Notice of Results
04 Nov 2014 07:00 AM
RNS
MEDIMMUNE ACQUIRES DEFINIENS

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings